19 November 2026 | Thursday | News
Image Source: Public Domain
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced a clinical trial collaboration and supply agreement (CTCSA) with Bristol Myers Squibb (NYSE: BMY, “BMS”) to evaluate Erasca’s potentially best-in-class pan-RAS molecular glue, ERAS-0015, with navlimetostat (BMS-986504), BMS’s investigational PRMT5 inhibitor.
Under the terms of this agreement, ERAS-0015 will be investigated in combination with navlimetostat in patients with MTAP-deleted (MTAPdel) pancreatic ductal adenocarcinoma (PDAC). BMS will sponsor the trial, and Erasca will supply ERAS-0015. The parties will retain development and commercial rights to their respective compounds, and the agreement is mutually non-exclusive.
“The early clinical activity demonstrated by ERAS-0015 has been encouraging, and we are excited to collaborate with BMS to further explore its potential in combination with navlimetostat, a clinical-stage investigational molecule with a compelling clinical profile,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “By bringing together complementary mechanisms with strong scientific rationale, this combination expands the potential of ERAS-0015 as a backbone of choice across RASm cancers and reinforces our strategy of pairing it with promising agents that may increase patient benefit. We look forward to working with BMS to advance this combination for patients with pancreatic cancer.”
Nearly all MTAP-deleted pancreatic cancers harbor co-occurring RAS mutations, creating a dependency that may make these tumors particularly susceptible to simultaneous RAS and PRMT5 inhibition. The combination of ERAS-0015 and navlimetostat may address the challenges in MTAPdel PDAC, while potentially enhancing antitumor activity.
© 2026 Biopharma Boardroom. All Rights Reserved.